WNTresearch
WNTresearch - WNT researchWNTresearchWNTresearchWNTresearch

WNT research

  • WntResearch
    • About WntResearch
    • Business concept and strategies
    • market Potential
    • Interview with the founder
    • History
    • Scientific advisors
  • Pipeline
    • Foxy-5
      • Phase 1 study
      • Phase 2 study
    • Articles
    • metastases
    • WNT signaling
    • Partners
      • SMS Oncology
      • Biovica
      • SAGA diagnostics
      • The Sage Group
    • Box-5
    • Patents
  • Investor
    • Financial reports
    • Warrants series 2021/2023
    • Share issues
    • The Share
    • presentations
    • Financial calendar
  • NEWS
    • Press Releases
    • Subscribe
  • Corporate Governance
    • Nomination committee
    • General meetings
    • Management
    • Board
    • Articles of association
  • Contact
  • English
    • Swedish

Blog Left Image

WNTresearch   →  Blog Left Image

Blog Left Image

Extraordinary General Meeting on Wednesday, March 10

Author By Jakob IvarssonPosted on February 5, 2021February 5, 2021
Link...

BioStock publishes interview with acting CEO!

Author By KatherinePosted on October 27, 2020October 27, 2020
Link...

Anders Rabbe is appointed acting CEO

Author By DavidPosted on October 1, 2020October 1, 2020
Link...

BioStock publishes interview with CEO Peter Morsing

Author By DavidPosted on September 24, 2020September 24, 2020
Link...

BioStock publishes summer interview with CEO Peter Morsing

Author By DavidPosted on July 9, 2020July 9, 2020
Link...

Wntresearch publishes quarterly report Q1 2020

Author By DavidPosted on April 17, 2020April 17, 2020
Link...

CEO interview about status in ongoing phase 2-study

Author By DavidPosted on April 15, 2020April 15, 2020
Link...

Biostock interviews the CEO

Author By DavidPosted on October 1, 2019October 9, 2019
...

A new approach to fight tumour spread!
Foxy-5 is a unique drug candidate:
Significant medical need, first-in-class, unique mode of action, excellent pharmacokinetics, strong preclinical efficacy data, favourable safety profile

QUICK LINKS

  • Phase 2 study
  • Press Releases
  • shares

Subscribe

Copyright © All rights reserved.